Log In
BCIQ
Print this Print this
 

DLX3003

  Manage Alerts
Collapse Summary General Information
Company Cell Medica Ltd.
DescriptionPentrabody against IL-17A
Molecular Target Interleukin-17A (IL-17A)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentDiscovery
Standard IndicationPsoriasis
Indication DetailsTreat psoriasis
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

07/12/2016

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today